12,584 Eli Lilly and Company $LLY Shares Acquired by Kestra Advisory Services LLC

Kestra Advisory Services LLC boosted its holdings in Eli Lilly and Company (NYSE:LLY) by 10.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 130,765 shares of the company’s stock after purchasing an additional 12,584 shares during the quarter. Kestra Advisory Services LLC’s holdings in Eli Lilly and Company were worth $151,306,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Torren Management LLC increased its stake in shares of Eli Lilly and Company by 357.1% during the 3rd quarter. Torren Management LLC now owns 32 shares of the company’s stock valued at $37,000 after acquiring an additional 25 shares during the last quarter. Marshall & Sterling Wealth Advisors Inc. boosted its position in shares of Eli Lilly and Company by 60.0% in the first quarter. Marshall & Sterling Wealth Advisors Inc. now owns 40 shares of the company’s stock worth $37,000 after acquiring an additional 15 shares during the last quarter. Foresight Capital Management Advisors Inc. acquired a new stake in shares of Eli Lilly and Company in the third quarter worth approximately $49,000. AlphaCentric Advisors LLC purchased a new stake in Eli Lilly and Company in the first quarter valued at approximately $42,000. Finally, Caitlin John LLC acquired a new position in Eli Lilly and Company during the second quarter worth approximately $64,000. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have weighed in on LLY. Bank of America reaffirmed a “buy” rating and set a $1,497.00 price target on shares of Eli Lilly and Company in a research note on Friday, October 30th. Citigroup boosted their price objective on shares of Eli Lilly and Company from $1,600.00 to $1,650.00 and gave the company a “buy” rating in a research note on Friday, October 30th. Argus upped their price objective on Eli Lilly and Company from $1,300.00 to $1,550.00 and gave the stock a “buy” rating in a report on Friday, October 30th. TD Cowen reaffirmed a “buy” rating and issued a $1,250.00 target price on shares of Eli Lilly and Company in a research report on Tuesday, September 22nd. Finally, Royal Bank Of Canada lifted their target price on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company an “outperform” rating in a report on Friday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $1,404.14.

Insider Buying and Selling

In related news, CAO Donald Zakrowski sold 2,000 shares of the stock in a transaction on Monday, August 10th. The stock was sold at an average price of $1,185.01, for a total value of $2,370,020.00. Following the completion of the sale, the chief accounting officer directly owned 1,526 shares in the company, valued at approximately $1,808,325.26. This represents a 56.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrik Jonsson sold 6,500 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total value of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 13,500 shares of company stock valued at $17,020,770. Company insiders own 0.14% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly and Hims & Hers agreed to offer FDA-approved Zepbound and Foundayo through Hims & Hers’ telehealth platform. Eligible patients with a prescription can access Lilly’s self-pay prices—reportedly starting at $149—without leaving the platform. The deal could widen patient access and Lilly’s reach in the competitive obesity-treatment market. Lilly and Hims & Hers expand access to FDA-approved Lilly medicines
• Positive Sentiment: New Phase 3 results for investigational retatrutide showed substantial reductions in weight and knee pain among adults with obesity and knee osteoarthritis. Lilly also reported positive Phase 3b results for combining Taltz and Zepbound in people with psoriatic arthritis and obesity, supporting the potential of its medicines in additional patient groups. Lilly to showcase new retatrutide, Taltz and Zepbound data
• Negative Sentiment: Price competition across the GLP-1 market remains a risk to Lilly’s growth and drug margins, as branded treatments compete with lower-priced options and providers seek self-pay patients. Eli Lilly’s GLP-1 franchise faces growing price competition

Eli Lilly and Company Trading Up 0.5%

NYSE LLY traded up $7.42 during mid-day trading on Friday, hitting $1,372.15. The company’s stock had a trading volume of 3,802,992 shares, compared to its average volume of 2,624,130. Eli Lilly and Company has a 52-week low of $850.51 and a 52-week high of $1,453.00. The stock’s fifty day simple moving average is $1,215.24 and its two-hundred day simple moving average is $1,101.16. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.39 and a quick ratio of 1.00. The firm has a market capitalization of $1.29 trillion, a P/E ratio of 44.54, a price-to-earnings-growth ratio of 1.77 and a beta of 0.40.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, October 29th. The company reported $7.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.71 by $1.77. Eli Lilly and Company had a net margin of 31.90% and a return on equity of 86.76%. The company had revenue of $24.40 billion during the quarter, compared to the consensus estimate of $22.58 billion. During the same period in the previous year, the firm earned $7.02 earnings per share. Eli Lilly and Company’s revenue for the quarter was up 38.6% on a year-over-year basis. Research analysts expect that Eli Lilly and Company will post 35.70 EPS for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, December 10th. Investors of record on Friday, November 13th will be given a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.5%. The ex-dividend date of this dividend is Friday, November 13th. Eli Lilly and Company’s dividend payout ratio is 22.46%.

About Eli Lilly and Company

Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for people and animals. Its work spans areas including diabetes and obesity, cancer, immunology, neuroscience and pain management.

The company’s medicines include treatments for diabetes and obesity, such as Mounjaro and Zepbound, as well as products for cancer and other conditions. Lilly also conducts research into new medicines and invests in the development of treatments across its therapeutic areas.

Founded in Indianapolis in 1876 by Colonel Eli Lilly, the company is headquartered in the city and serves patients in markets around the world.